Group 1 - The company has established a joint investment with AglaeaPharma to set up Guangxi Aglaea, focusing on multi-target small molecule compound drug screening and early disease detection and diagnostic technology development [2] - AglaeaPharma's project platform has developed multiple technology platforms, product pipelines, and a series of products, forming a globally integrated innovative research and development system [2] - The company will continue to monitor the project's progress and fulfill its information disclosure obligations in a timely manner [2]

Financial Data and Key Metrics Changes - Net sales increased by 10.1% at constant exchange rates in Q2 2025, primarily driven by immunology, biopharma launches, and Befortus [15][25] - Business EPS was €1.59, up 8.3%, reflecting strong sales performance and improved gross margin [15][25] - Gross margin improved by 1.5 percentage points due to an improved product mix and efficiencies [15] Business Line Data and Key Metrics Changes - New launches generated close to €1,000,000,000 in sales, representing 10% of total sales [6][7] - Dupixent sales reached €3,800,000,000, up 21% in Q2, driven by strong demand across geographies [7][8] - Vaccine business sales increased by 10.3%, benefiting from the late flu season in the Northern Hemisphere [9][10] Market Data and Key Metrics Changes - Dupixent sales in the U.S. reached €2,800,000,000, up 22.7%, leading in both new to brand prescriptions and total prescriptions [8] - Outside the U.S., sales exceeded $1,000,000,000, driven by volume growth in key markets [8] - Anticipated sales split for flu vaccines is about 75% in Q3 and 25% in Q4, with total sales expected to decrease by a mid-teens percentage due to competitive pressures [24][25] Company Strategy and Development Direction - The company refined its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, reflecting confidence in growth drivers [5][25] - The completion of the Blueprint Medicines acquisition strengthens the company's position in rare immunology diseases and enhances its pipeline [12][18] - The company is committed to sustainability, aiming for all new medicines and vaccines to incorporate eco-design principles by 2025 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the full-year business outlook, supported by strong performance from growth drivers [5][25] - The company is navigating uncertainties from potential U.S. tariffs and EU exports, with updates to be provided as more information becomes available [26] - Management highlighted the importance of maintaining a strong market share despite competitive pricing pressures in the flu vaccine market [24][25] Other Important Information - The company is executing a €5,000,000,000 share buyback program in 2025, with over 80% already completed [20] - The anticipated negative year-on-year BOI impact from Regeneron reimbursement is approximately €300,000,000 in 2026 and €800,000,000 in 2027 [22] Q&A Session Summary Question: R&D transformation and pipeline progress - Management acknowledged the progress in R&D but noted that the share price is lagging, indicating a need for pipeline advancements [42][43] - Confidence remains in achieving the targeted increase in Phase III trials and the potential for significant sales by 2030 [43][46] Question: Development spend and pricing pressures - R&D expenses are expected to be slightly up in H2, with SG&A increasing at half the rate of sales growth [51][55] - Management confirmed that pricing pressures in the flu market are being addressed, with expectations for continued market share despite competitive dynamics [72][75] Question: Dupixent growth in China - Dupixent has seen over 30% volume growth in China, with management optimistic about future growth despite pricing pressures [60][62] Question: Expectations for amlitelemab and tariffs - Management emphasized the importance of efficacy and treatment duration for amlitelemab in the atopic dermatitis market [68][69] - No significant impact from tariffs is expected for 2025 due to existing inventory [66][67]

杜萨表示，瑞典支持多边主义和自由贸易，视中国为重要经贸伙伴，鼓励瑞中双方企业进一步深化 绿色转型、创新研发等领域合作，支持欧盟与中国通过协商解决经贸摩擦，推动欧中、瑞中经贸关系迈 上新台阶。 人民网斯德哥尔摩7月30日电 （记者殷淼）7月30日，国际贸易谈判代表兼副部长李成钢在瑞典斯 德哥尔摩会见瑞典对外援助与外贸大臣杜萨，双方就中瑞、中欧经贸关系等议题进行交流。 李成钢表示，瑞典是首个与新中国建交的西方国家，也是首个与中国签订双边投资保护协定的国 家。今年是两国建交75周年，中方愿与瑞方一道，推动中瑞经贸合作翻开新的篇章。中国对外开放的大 门只会越开越大，愿进一步扩大瑞典优质商品进口，欢迎瑞典担任今年进博会主宾国，也欢迎瑞典企业 继续投资中国、深耕中国，希望瑞方为中国企业提供开放、公平、非歧视的营商环境。同时，希望瑞方 在欧盟内发挥积极作用，推动欧方与中方共同落实好中欧领导人会晤达成的共识，坚定维护以世贸组织 为核心的多边贸易体制，并妥善解决经贸摩擦。 ...

编辑 陈艳婷 据央视新闻消息，7月30日，商务部国际贸易谈判代表兼副部长李成钢在斯德哥尔摩会见瑞典对外援助 与外贸大臣杜萨，双方就中瑞、中欧经贸关系等议题进行交流。 杜萨表示，瑞典支持多边主义和自由贸易，视中国为重要经贸伙伴，鼓励瑞中双方企业进一步深化绿色 转型、创新研发等领域合作，支持欧盟与中国通过协商解决经贸摩擦，推动欧中、瑞中经贸关系迈上新 台阶。 李成钢表示，瑞典是首个与新中国建交的西方国家，也是首个与中国签订双边投资保护协定的国家。今 年是两国建交75周年，中方愿与瑞方一道，推动中瑞经贸合作翻开新的篇章。中国对外开放的大门只会 越开越大，愿进一步扩大瑞典优质商品进口，欢迎瑞典担任今年进博会主宾国，也欢迎瑞典企业继续投 资中国、深耕中国，希望瑞方为中国企业提供开放、公平、非歧视的营商环境。同时，希望瑞方在欧盟 内发挥积极作用，推动欧方与中方共同落实好中欧领导人会晤达成的共识，坚定维护以世贸组织为核心 的多边贸易体制，并妥善解决经贸摩擦。 ...

李成钢表示，瑞典是首个与新中国建交的西方国家，也是首个与中国签订双边投资保护协定的国家。今 年是两国建交75周年，中方愿与瑞方一道，推动中瑞经贸合作翻开新的篇章。中国对外开放的大门只会 越开越大，愿进一步扩大瑞典优质商品进口，欢迎瑞典担任今年进博会主宾国，也欢迎瑞典企业继续投 资中国、深耕中国，希望瑞方为中国企业提供开放、公平、非歧视的营商环境。同时，希望瑞方在欧盟 内发挥积极作用，推动欧方与中方共同落实好中欧领导人会晤达成的共识，坚定维护以世贸组织为核心 的多边贸易体制，并妥善解决经贸摩擦。 杜萨表示，瑞典支持多边主义和自由贸易，视中国为重要经贸伙伴，鼓励瑞中双方企业进一步深化绿色 转型、创新研发等领域合作，支持欧盟与中国通过协商解决经贸摩擦，推动欧中、瑞中经贸关系迈上新 台阶。 7月30日，李成钢国际贸易谈判代表兼副部长在斯德哥尔摩会见瑞典对外援助与外贸大臣杜萨，双方就 中瑞、中欧经贸关系等议题进行交流。 ...

Core Viewpoint - The meeting between China's Vice Minister of International Trade Negotiations, Li Chenggang, and Sweden's Minister for Foreign Aid and Trade, Johan Forssell, emphasizes the importance of strengthening economic and trade relations between China and Sweden, particularly in light of the 75th anniversary of diplomatic relations [1] Group 1: Economic Cooperation - China expresses willingness to expand imports of high-quality Swedish goods and welcomes Sweden as the guest country for this year's China International Import Expo [1] - Both parties aim to deepen cooperation in areas such as green transformation and innovative research and development [1] Group 2: Trade Environment - China requests Sweden to provide an open, fair, and non-discriminatory business environment for Chinese enterprises [1] - Sweden supports multilateralism and free trade, viewing China as an important economic partner [1] Group 3: EU Relations - China hopes Sweden will play a positive role within the EU to facilitate the implementation of agreements reached during China-EU leadership meetings [1] - Both sides agree on the importance of resolving trade frictions through consultation and maintaining a multilateral trade system centered around the WTO [1]

Production Capacity and Resource Matching - The company has six production bases located in Shanghai, Hefei, Hengyang, Zhengzhou, Wenzhou, and Nanning, with Shanghai, Hefei, and Hengyang being the largest [2] - Current production capacity matches the plasma collection volume, with ongoing expansion projects, such as the Shanghai base, designed to increase capacity to over 1,500 tons per year [2] Plasma Station and Resource Development - Prior to the acquisition of Nanyue Biological, the company had a total of 44 plasma collection stations, with Nanyue adding 9 more, distributed across 11 provinces [3] - The company focuses on both optimizing existing plasma stations and expanding new ones to ensure continuous growth in plasma collection [4] Market Conditions and Product Demand - The blood product market currently has a certain level of inventory among companies and distributors [5] - Sales of human albumin have slightly slowed due to healthcare policies and supply-demand dynamics, but there remains a rigid demand for its various medical applications [6] Pricing and Innovation - Blood product prices have experienced slight changes influenced by policy and supply-demand factors, with the company monitoring market dynamics to maintain reasonable pricing [7] - The company is committed to innovation, focusing on both "plasma expansion" and "plasma extraction," with ongoing clinical research on SR604 injection, currently in Phase IIb trials [8] Strategic Partnerships - In March 2019, the company signed an exclusive strategic cooperation agreement with Klibor, leading to collaborative efforts in quality management and product distribution, positively impacting performance [9]

Core Viewpoint - Songlin Technology (603992.SH) achieved a record profit of 446 million yuan in 2024, and is focusing on the robotics sector in 2025 despite facing short-term external pressures and a decline in revenue from key sales regions due to macroeconomic factors and international trade policy changes [1] Group 1: Business Developments - The company launched its Vietnam production base in June 2025, enhancing its global layout and mitigating the impact of US-China trade tensions, which opens new export growth opportunities and strengthens the resilience of its global supply chain [2] - Songlin Technology is strategically entering the robotics sector by acquiring Xiamen Weidis Intelligent Motion Systems Co., aiming to leverage combined resources for rapid development in this promising new business area [3] - The company maintains high R&D investment, increasing its expenditure to 225 million yuan in 2024, and holds 1,337 valid domestic and international patents, focusing on innovation in robotics, health technology, and smart kitchen and bathroom products [4] Group 2: Market Performance - The company continues to see strong growth in emerging markets, validating its market expansion strategy, and is committed to its "Three Three One" strategy to explore new markets and customers [5] - The recent profit reduction is attributed to short-term revenue fluctuations and strategic investments, but future growth is expected from the release of Vietnam's production capacity and the development of new health technology and robotics businesses [5]

Core Viewpoint - Dongyangguang Pharmaceutical Co., Ltd. is set to return to the capital market with a new positioning as an innovative pharmaceutical company through a "introduction listing" on the Hong Kong Stock Exchange, aiming to list 112.7 million H shares by August 7, 2025, following its privatization [1] Group 1: Company Transformation and R&D Focus - The company has successfully transformed by focusing on innovative drug research and development, showcasing resilience and growth [1] - Dongyangguang has established the only national key laboratory for the research and development of new anti-infection drugs in Guangdong Province, equipped with over 50,000 square meters of laboratory space and more than 400 high-performance liquid chromatography instruments [1] - The company has maintained a high investment in R&D, with over 20% of its revenue allocated to R&D in 2024, leading to breakthroughs in core technologies and breaking foreign technology monopolies [2] Group 2: Innovation and AI Integration - Dongyangguang ranks first among domestic pharmaceutical companies in the number of patents published and granted in China from 2014 to 2023 [2] - The company is actively integrating AI technology to enhance R&D efficiency, with the first candidate drug HEC169584 developed through an AI-driven platform currently in clinical trials [2] Group 3: Organizational Culture and Competitive Advantage - The company emphasizes expert-led decision-making and team practices to build core competencies, allowing experts to focus on technical areas without administrative duties [3] - The organizational culture, established by founder Zhang Zhongneng, promotes resilience and confidence, which has helped attract and motivate talent [3] - Dongyangguang has developed a mature system covering three major fields and the entire R&D lifecycle, achieving a leap towards "systematic innovation" [3]

Core Viewpoint - The recent announcement by the Shanghai Medical Insurance Bureau regarding the adjustment of coronary stent reimbursement standards is expected to provide new ideas for diversified payment methods in the industry [1][5]. Group 1: Policy Changes - The new reimbursement rules categorize coronary stents into three payment categories: full reimbursement for selected products, a reduced maximum payment for non-selected products, and a percentage payment for products outside the selection [1][5]. - The policy aims to create a competitive environment for high-value innovative devices alongside selected products, potentially increasing their market presence [1][5]. Group 2: Market Impact - The shift in policy is seen as beneficial for non-selected products, allowing hospitals more freedom to use them after fulfilling procurement obligations for selected products [2][5]. - The coronary stent market has experienced significant price reductions due to centralized procurement, with average prices dropping from approximately 13,000 yuan to around 700 yuan [3][4]. Group 3: Industry Dynamics - The coronary intervention medical device sector is highly competitive, with domestic and international companies vying for market share through technological advancements and product offerings [6][7]. - Companies like Sientra have reported substantial growth in sales of their stent products, indicating a positive response to the new procurement policies [6][7]. Group 4: Future Outlook - The industry is expected to focus on innovation and international expansion as key strategies for growth, with companies exploring new business models and enhancing product lines [7][8]. - The global medical device market is substantial, with opportunities for Chinese companies to expand their presence internationally, driven by policy adjustments and technological advancements [8].